Treatment of osteoporosis

Details Treatment of osteoporosis Treatment of osteoporosis

1996-02-15

1999-08-10

Moezie, M.

Drug, bio-affecting and body treating compositions

Inorganic active ingredient containing

Phosphorus or phosphorus compound

424602, 424603, 424604, 424606, A61K 3342

Patent

active

059356073

ABSTRACT:
A method of treating osteoporosis is disclosed by administering orally a single daily dosage of phosphate in the evening in an amount, e.g., about 10 mg/kg body weight or less which is effective to raise serum parathyroid hormone levels of the subject being treated.

REFERENCES:
patent: 4833125 (1989-05-01), Neer et al.
patent: 5409911 (1995-04-01), Tyler et al.
Naveh-Many et al, J. Clin, Inves. 90: 2434-2438 (1992).
Rodan, G.A., Mechanical loading, estrogen deficiency, and the coupling of ne formation to bone resorption J. Bone Miner, Res., 6: 527-530, 1991.
Juppner, H., Abou-Samra, A.B., Freeman, M., Kong, X.F., Schipani, E., Richards, J., Kolakowski, L.F., Hocks, J., Potts, J.T., Kronenberg, H.M., and Segre, G.V., A Gprotein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide, Science, 254: 1024-1026, 1991.
Mosekilde, Li, Danielsen, et al, The Anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in a sexually mature, ovariectomized rat model, Bone, 16: 223-230, 1995.
Reeve, J., et al., Anabolic effects of human parathyroid hormone fragment on trabecular bone in involution osteoporosis: A multicentre trial, Br. Med. J., 280: 1340-1344, 1980.
Dempster, et al, Anabolic actions of parathyroid hormone on bone, Endocrine Rev., 14: 690-709, 1993.
Finkelstein, J.S. et al, Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency New Eng. J. Med., 331: 1618-1623, 1994.
Prank, S., et al, Time series prediction of plasma hormone concentration. Evidence for differences in predictability of parathyroid hormone secretion between osteoporotic patients and normal controls, J. Clin, Invest., 95, 2910-2919, 1995.
Silver, et al., J. Clin. Inves. 78: 1296-1301 (1986).
Okazaki et al., J. Biol. Chem. 269: 27855-62 (1994).
Pe'er et al., Opthalmology, 101: 56-62 (1994).
Gavrieli et al., J. Cell Bio. 119: 493-501 (1992).
Naveh-Many, Tally et al., Parathyroid Cell Proliferation in Normal and Chronic Renal Failure Rats, J. Clin. Invest., vol. 96, Oct. 1995, 1786-1793.
Kilav, R. et al., Parathyroid Hormone Gene Expression in Hypophosphatemic Rats, J. Clin. Invest., vol. 96, Jul. 1995, 327-333.
Marie, P.J., et al., Mechanisms Underlying the Effects of Phosphate and Calcitonin on Bone Histology in Postmenopausal Osteoporosis, Bone, 7, pp. 17-22 (1986).
Budavari et al. "The Merck Index" (11.sup.th Ed.) Merck and Co, Inc., Rahway, N.J. (1989) pp. 1166-1167, 1216-1217 and 1366-1367.
Goodman Gilman et al., "The Pharmacological Basis of Therapeutics" (6.sup.th Ed.) 1980, Macmillan, NY, pp. 1529-1535.
Hebert, Lee A. et al., "Studies of the Mechanism by Which Phosphate Infusion Lowers Serum Calcium Concentration," J. Clin. Invest., vol. 45, No. 12 (1966) pp. 1886-1894.
Raisz, Lawrence G. et al., "Effects of Phosphate on Bone Formation and Resorption in Tissue Culture," Phosphate Metabolism, Kidney and Bone. L.V. Avoli, ed., Armour-Montagu, Paris, pp. 213-221, 1975.

Affiliated with

Also associated with

Rating

Treatment of osteoporosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of osteoporosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of osteoporosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1117751